RxDoctor Payments Data

Claire Hunt, PA

Medical · Hampton, VANPI 1497470686

Payments from drug & device makers

$717in general payments, 2019–2025

Across 27 payments — averaging $26.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$248
  • Astellas Pharma US Inc$152
  • AbbVie$86
  • Pfizer$66
  • Novo Nordisk$58
  • Impel Pharmaceuticals Inc.$40
  • plus $68 from 3 others

What the payments were for

  • Food & beverage$717100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$717 in reported general payments places this provider in the 55th percentile of 632 medical providers in Virginia.

See all medical providers in Virginia

Medicare billing

Part B allowed, 2024
$21,405
Medicare patients
134
Services billed
212

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide18$32,244
VascepaIcosapent Ethyl13$8,252
FarxigaDapagliflozin Propanediol11$7,397
Rosuvastatin Calcium46$873
Ipratropium Bromide12$670
Levothyroxine Sodium52$651
Azelastine Hcl11$541
Atorvastatin Calcium29$415
Losartan Potassium42$402
ValacyclovirValacyclovir Hcl17$387
Gabapentin24$369
Albuterol Sulfate HfaAlbuterol Sulfate12$359
Omeprazole14$315
Pantoprazole Sodium22$288
Trazodone Hcl18$202

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$58$32,24418 claims
AstraZenecaFarxiga$36$7,39711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 632 medical providers in Virginia.

Other medical in Hampton

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →